Skip to main content
Top
Published in: Diabetologia 5/2010

Open Access 01-05-2010 | Article

Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress

Authors: O. Brouwers, P. M. Niessen, G. Haenen, T. Miyata, M. Brownlee, C. D. Stehouwer, J. G. De Mey, C. G. Schalkwijk

Published in: Diabetologia | Issue 5/2010

Login to get access

Abstract

Aims/hypothesis

Impaired nitric oxide (NO)-dependent vasorelaxation plays a key role in the development of diabetic vascular complications. We investigated the effect of hyperglycaemia on impaired vasoreactivity and a putative role therein of the AGE precursor methylglyoxal.

Methods

The effects of high glucose and methylglyoxal on NO-dependent vasorelaxation in isolated rat mesenteric arteries from wild-type and transgenic glyoxalase (GLO)-I (also known as GLO1) rats, i.e. the enzyme detoxifying methylglyoxal, were recorded in a wire myograph. AGE formation of the major methylglyoxal-adduct 5-hydro-5-methylimidazolone (MG-H1) was detected with an antibody against MG-H1 and quantified with ultra-performance liquid chromatography (tandem) mass spectrometry. Reactive oxygen species formation was measured with a 5-(and-6)-chloromethyl-2′7′-dichlorodihydrofluorescein diacetate acetyl ester probe and by immunohistochemistry with an antibody against nitrotyrosine.

Results

High glucose and methylglyoxal exposure of mesenteric arteries significantly reduced the efficacy of NO-dependent vasorelaxation (p < 0.05). This impairment was not observed in mesenteric arteries of GLO-I transgenic rats indicating a specific intracellular methylglyoxal effect. The diabetes-induced impaired potency (pD2) in mesenteric arteries of wild-type rats was significantly improved by GLO-I overexpression (p < 0.05). Methylglyoxal-modified albumin did not affect NO-dependent vasorelaxation, while under the same conditions the receptor for AGE ligand S100b did (p < 0.05). Methylglyoxal treatment of arteries increased intracellular staining of MG-H1 in endothelial cells and adventitia by fivefold accompanied by an eightfold increase in the oxidative stress marker nitrotyrosine. Antioxidant pre-incubation prevented methylglyoxal-induced impairment of vasoreactivity.

Conclusions/interpretation

These data show that hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation is mediated by increased intracellular methylglyoxal levels in a pathway dependent on oxidative stress.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schalkwijk CG, Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143–159CrossRef Schalkwijk CG, Stehouwer CD (2005) Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143–159CrossRef
2.
go back to reference Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–2610CrossRefPubMed Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–2610CrossRefPubMed
3.
go back to reference Makimattila S, Virkamaki A, Groop PH et al (1996) Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94:1276–1282PubMed Makimattila S, Virkamaki A, Groop PH et al (1996) Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 94:1276–1282PubMed
4.
go back to reference Diederich D, Skopec J, Diederich A, Dai FX (1994) Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 266:H1153–H1161PubMed Diederich D, Skopec J, Diederich A, Dai FX (1994) Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 266:H1153–H1161PubMed
5.
go back to reference Pflueger AC, Osswald H, Knox FG (1999) Adenosine-induced renal vasoconstriction in diabetes mellitus rats: role of nitric oxide. Am J Physiol 276:F340–F346PubMed Pflueger AC, Osswald H, Knox FG (1999) Adenosine-induced renal vasoconstriction in diabetes mellitus rats: role of nitric oxide. Am J Physiol 276:F340–F346PubMed
6.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed
7.
go back to reference Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y (1998) Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications. Diabetes Care 21:1027CrossRefPubMed Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y (1998) Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications. Diabetes Care 21:1027CrossRefPubMed
8.
go back to reference Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG (1999) Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 42:603–607CrossRefPubMed Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG (1999) Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 42:603–607CrossRefPubMed
9.
go back to reference Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543–1548CrossRefPubMed Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543–1548CrossRefPubMed
10.
go back to reference Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25:1055–1059CrossRefPubMed Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS (2002) Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25:1055–1059CrossRefPubMed
11.
go back to reference Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A (2003) Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 17:1289–1291CrossRefPubMed Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A (2003) Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 17:1289–1291CrossRefPubMed
12.
go back to reference Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS (2003) Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31:1358–1363CrossRefPubMed Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS (2003) Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 31:1358–1363CrossRefPubMed
13.
go back to reference Shinohara M, Thornalley PJ, Giardino I et al (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142–1147CrossRefPubMed Shinohara M, Thornalley PJ, Giardino I et al (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142–1147CrossRefPubMed
14.
go back to reference Thornalley PJ (2003) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348CrossRefPubMed Thornalley PJ (2003) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348CrossRefPubMed
15.
go back to reference Oya T, Hattori N, Mizuno Y et al (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 274:18492–18502CrossRefPubMed Oya T, Hattori N, Mizuno Y et al (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 274:18492–18502CrossRefPubMed
16.
go back to reference Ahmed N, Thornalley PJ (2002) Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 364:15–24PubMed Ahmed N, Thornalley PJ (2002) Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 364:15–24PubMed
17.
go back to reference McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 87:21–29 McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 87:21–29
18.
go back to reference Schalkwijk CG, van Bezu J, van der Schors RC, Uchida K, Stehouwer CD, van Hinsbergh VW (2006) Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 580:1565–1570CrossRefPubMed Schalkwijk CG, van Bezu J, van der Schors RC, Uchida K, Stehouwer CD, van Hinsbergh VW (2006) Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 580:1565–1570CrossRefPubMed
19.
go back to reference Mostafa AA, Randell EW, Vasdev SC et al (2007) Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 302:35–42CrossRefPubMed Mostafa AA, Randell EW, Vasdev SC et al (2007) Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 302:35–42CrossRefPubMed
20.
go back to reference Fosmark DS, Torjesen PA, Kilhovd BK et al (2006) Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55:232–236CrossRefPubMed Fosmark DS, Torjesen PA, Kilhovd BK et al (2006) Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55:232–236CrossRefPubMed
21.
go back to reference Wang X, Chang T, Jiang B, Desai K, Wu L (2007) Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. Am J Hypertens 20:629–636CrossRefPubMed Wang X, Chang T, Jiang B, Desai K, Wu L (2007) Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. Am J Hypertens 20:629–636CrossRefPubMed
22.
go back to reference Wang X, Desai K, Chang T, Wu L (2005) Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 23:1565–1573CrossRefPubMed Wang X, Desai K, Chang T, Wu L (2005) Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 23:1565–1573CrossRefPubMed
23.
go back to reference Wang X, Desai K, Clausen JT, Wu L (2004) Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 66:2315–2321CrossRefPubMed Wang X, Desai K, Clausen JT, Wu L (2004) Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 66:2315–2321CrossRefPubMed
24.
go back to reference Wang X, Jia X, Chang T, Desai K, Wu L (2008) Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 26:765–772CrossRefPubMed Wang X, Jia X, Chang T, Desai K, Wu L (2008) Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 26:765–772CrossRefPubMed
25.
go back to reference Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809–814CrossRefPubMed Wu L, Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809–814CrossRefPubMed
26.
go back to reference Nemet I, Varga-Defterdarovic L, Turk Z (2006) Methylglyoxal in food and living organisms. Mol Nutr Food Res 50:1105–1117CrossRefPubMed Nemet I, Varga-Defterdarovic L, Turk Z (2006) Methylglyoxal in food and living organisms. Mol Nutr Food Res 50:1105–1117CrossRefPubMed
27.
go back to reference Rosca MG, Mustata TG, Kinter MT et al (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289:F420–F430CrossRefPubMed Rosca MG, Mustata TG, Kinter MT et al (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289:F420–F430CrossRefPubMed
28.
go back to reference Inagi R, Miyata T, Ueda Y et al (2002) Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int 62:679–687CrossRefPubMed Inagi R, Miyata T, Ueda Y et al (2002) Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int 62:679–687CrossRefPubMed
29.
go back to reference Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG (2009) Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 877:610–614CrossRefPubMed Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG (2009) Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 877:610–614CrossRefPubMed
30.
go back to reference Fontijn R, Hop C, Brinkman HJ et al (1995) Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 216:199–207CrossRefPubMed Fontijn R, Hop C, Brinkman HJ et al (1995) Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 216:199–207CrossRefPubMed
31.
go back to reference McLellan AC, Phillips SA, Thornalley PJ (1993) The assay of S-d-lactoylglutathione in biological systems. Anal Biochem 211:37–43CrossRefPubMed McLellan AC, Phillips SA, Thornalley PJ (1993) The assay of S-d-lactoylglutathione in biological systems. Anal Biochem 211:37–43CrossRefPubMed
32.
go back to reference Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A (1997) A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds. Pharm World Sci 19:283–286CrossRefPubMed Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A (1997) A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds. Pharm World Sci 19:283–286CrossRefPubMed
33.
go back to reference Cooke JP, Dzau VJ (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48:489–509CrossRefPubMed Cooke JP, Dzau VJ (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48:489–509CrossRefPubMed
34.
go back to reference Taylor PD, Poston L (1994) The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 113:801–808PubMed Taylor PD, Poston L (1994) The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 113:801–808PubMed
35.
go back to reference Mukohda M, Yamawaki H, Nomura H, Okada M, Hara Y (2009) Methylglyoxal inhibits smooth muscle contraction in isolated blood vessels. J Pharmacol Sci 109:305–310CrossRefPubMed Mukohda M, Yamawaki H, Nomura H, Okada M, Hara Y (2009) Methylglyoxal inhibits smooth muscle contraction in isolated blood vessels. J Pharmacol Sci 109:305–310CrossRefPubMed
36.
go back to reference Berlanga J, Cibrian D, Guillen I et al (2005) Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109:83–95CrossRef Berlanga J, Cibrian D, Guillen I et al (2005) Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109:83–95CrossRef
37.
go back to reference Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW (2006) Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 95:320–328PubMed Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW (2006) Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 95:320–328PubMed
38.
go back to reference Gao X, Zhang H, Schmidt AM, Zhang C (2008) AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 295:H491–H498CrossRefPubMed Gao X, Zhang H, Schmidt AM, Zhang C (2008) AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 295:H491–H498CrossRefPubMed
39.
go back to reference Ceradini DJ, Yao D, Grogan RH et al (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283:10930–10938CrossRefPubMed Ceradini DJ, Yao D, Grogan RH et al (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283:10930–10938CrossRefPubMed
40.
go back to reference Yao D, Taguchi T, Matsumura T et al (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282:31038–31045CrossRefPubMed Yao D, Taguchi T, Matsumura T et al (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282:31038–31045CrossRefPubMed
41.
go back to reference Schlotterer A, Kukudov G, Bozorgmehr F et al (2009) C. elegans as model for the study of high glucose mediated lifespan reduction. Diabetes 58:2450–2456CrossRefPubMed Schlotterer A, Kukudov G, Bozorgmehr F et al (2009) C. elegans as model for the study of high glucose mediated lifespan reduction. Diabetes 58:2450–2456CrossRefPubMed
42.
go back to reference Thornalley PJ, Battah S, Ahmed N et al (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581–592CrossRefPubMed Thornalley PJ, Battah S, Ahmed N et al (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581–592CrossRefPubMed
43.
go back to reference Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed
44.
go back to reference Vincent AM, Brownlee M, Russell JW (2002) Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 959:368–383PubMedCrossRef Vincent AM, Brownlee M, Russell JW (2002) Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 959:368–383PubMedCrossRef
45.
go back to reference Su J, Lucchesi PA, Gonzalez-Villalobos RA et al (2008) Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 28:1432–1438CrossRefPubMed Su J, Lucchesi PA, Gonzalez-Villalobos RA et al (2008) Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 28:1432–1438CrossRefPubMed
46.
go back to reference Heumuller S, Wind S, Barbosa-Sicard E et al (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51:211–217CrossRefPubMed Heumuller S, Wind S, Barbosa-Sicard E et al (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51:211–217CrossRefPubMed
47.
go back to reference Choudhary D, Chandra D, Kale RK (1997) Influence of methylglyoxal on antioxidant enzymes and oxidative damage. Toxicol Lett 93:141–152CrossRefPubMed Choudhary D, Chandra D, Kale RK (1997) Influence of methylglyoxal on antioxidant enzymes and oxidative damage. Toxicol Lett 93:141–152CrossRefPubMed
48.
go back to reference Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ (2005) Methylglyoxal can modify GAPDH activity and structure. Ann N Y Acad Sci 1043:135–145CrossRefPubMed Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ (2005) Methylglyoxal can modify GAPDH activity and structure. Ann N Y Acad Sci 1043:135–145CrossRefPubMed
49.
go back to reference Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432–438CrossRefPubMed Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432–438CrossRefPubMed
50.
go back to reference Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr (1998) Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 273:18709–18713CrossRefPubMed Liu X, Miller MJ, Joshi MS, Sadowska-Krowicka H, Clark DA, Lancaster JR Jr (1998) Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 273:18709–18713CrossRefPubMed
51.
go back to reference Brouwers O, Teerlink T, van Bezu J, Barto R, Stehouwer C, Schalkwijk C (2007) Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase. Ann N Y Acad Sci 1126:231–234CrossRefPubMed Brouwers O, Teerlink T, van Bezu J, Barto R, Stehouwer C, Schalkwijk C (2007) Methylglyoxal and methylglyoxal-arginine adducts do not directly inhibit endothelial nitric oxide synthase. Ann N Y Acad Sci 1126:231–234CrossRefPubMed
52.
go back to reference Lapolla A, Flamini R, Dalla Vedova A et al (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41:1166–1173CrossRefPubMed Lapolla A, Flamini R, Dalla Vedova A et al (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41:1166–1173CrossRefPubMed
53.
go back to reference Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49:685–690CrossRefPubMed Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49:685–690CrossRefPubMed
54.
go back to reference Chaplen FW, Fahl WE, Cameron DC (1998) Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 95:5533–5538CrossRefPubMed Chaplen FW, Fahl WE, Cameron DC (1998) Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci U S A 95:5533–5538CrossRefPubMed
55.
go back to reference Randell EW, Vasdev S, Gill V (2005) Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J Pharmacol Toxicol Methods 51:153–157CrossRefPubMed Randell EW, Vasdev S, Gill V (2005) Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J Pharmacol Toxicol Methods 51:153–157CrossRefPubMed
Metadata
Title
Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress
Authors
O. Brouwers
P. M. Niessen
G. Haenen
T. Miyata
M. Brownlee
C. D. Stehouwer
J. G. De Mey
C. G. Schalkwijk
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1677-0

Other articles of this Issue 5/2010

Diabetologia 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.